Hepatic Recurrence of Neuroendocrine Tumor Component in Gallbladder Cancer

A 60-year-old man underwent an extended cholecystectomy with regional lymphadenectomy for T2N0M0 gallbladder cancer (GBC), which showed significant FDG uptake (SUV max = 6.5). However, CT scan at 24 months postsurgery revealed multiple hepatic masses. Unlike the primary GBC, the hepatic masses showed limited FDG uptake (SUV max = 3.7). A tumor biopsy revealed the diagnosis of a grade 3 neuroendocrine tumor. Furthermore, the hepatic masses showed significant uptake on somatostatin receptor scintigraphy. Upon reevaluation, the primary resected specimen was found to include approximately 10% of neuroendocrine tumor components. This case suggests that different FDG uptake between primary and metastatic cancer may necessitate differential diagnosis.

Authors

Institutions

Publication Details

Journal
Clinical Nuclear Medicine
Published
2024-10-21
DOI
https://doi.org/10.1097/rlu.0000000000005539
Citations
1
Primary Topic
Neuroendocrine Tumor Research Advances
Type
article
Field-Weighted Citation Impact
0.39
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Hepatic Recurrence of Neuroendocrine Tumor Component in Gallbladder Cancer

Kazuyuki Nagai, Thales Akio Ikejiri, Etsuro Hatano, Yosuke Kasai et al.
1 citations
Clinical Nuclear Medicine
Neuroendocrine Tumor Research Advances
0.39
article

Hepatic Recurrence of Neuroendocrine Tumor Component in Gallbladder Cancer

Kazuyuki Nagai, Thales Akio Ikejiri, Etsuro Hatano, Yosuke Kasai, Tomoaki Yoh
article en
1 citations

Abstract

A 60-year-old man underwent an extended cholecystectomy with regional lymphadenectomy for T2N0M0 gallbladder cancer (GBC), which showed significant FDG uptake (SUV max = 6.5). However, CT scan at 24 months postsurgery revealed multiple hepatic masses. Unlike the primary GBC, the hepatic masses showed limited FDG uptake (SUV max = 3.7). A tumor biopsy revealed the diagnosis of a grade 3 neuroendocrine tumor. Furthermore, the hepatic masses showed significant uptake on somatostatin receptor scintigraphy. Upon reevaluation, the primary resected specimen was found to include approximately 10% of neuroendocrine tumor components. This case suggests that different FDG uptake between primary and metastatic cancer may necessitate differential diagnosis.

Clinical Nuclear MedicineVol. 50(3)
Kyoto University (JP)
Good health and well-being
Openalex Percentile: Top 33%
Neuroendocrine Tumor Research Advances
0.39
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Hepatic Recurrence of Neuroendocrine Tumor Component in Gallbladder Cancer — Kazuyuki Nagai, Thales Akio Ikejiri, et al. · Clinical Nuclear Medicine (2024) | TGRS Research Map | TGRS